CSL Limited (OTCMKTS:CSLLY – Get Free Report) saw a significant decrease in short interest in September. As of September 30th, there was short interest totalling 400 shares, a decrease of 90.5% from the September 15th total of 4,200 shares. Based on an average trading volume of 28,400 shares, the days-to-cover ratio is currently 0.0 days.
CSL Price Performance
CSLLY traded up $1.02 on Friday, hitting $100.19. The company had a trading volume of 18,473 shares, compared to its average volume of 29,765. The stock has a fifty day simple moving average of $101.12 and a 200-day simple moving average of $97.36. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18. CSL has a 52-week low of $71.51 and a 52-week high of $109.00.
Wall Street Analysts Forecast Growth
Separately, Macquarie upgraded shares of CSL to a “strong-buy” rating in a report on Tuesday, August 13th.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Articles
- Five stocks we like better than CSL
- What is a SEC Filing?
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Most Volatile Stocks, What Investors Need to Know
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- The 3 Best Fintech Stocks to Buy Now
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
